Next Article in Journal
Genotype-Phenotype Correlation of β-Thalassemia Spectrum of Mutations in an Indian Population
Previous Article in Journal
Hematological Profile of Sickle Cell Disease from South Gujarat, India
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 4
Issue 2
10.4081/hr.2012.e10
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Romiplostim as Early Treatment of Immune Thrombocytopenia with Severe Immunodeficiency

by
Francesca Palandri
1,*,
Nicola Polverelli
1,
Francesca Lifrieri
2,
Lucia Catani
1,
Maria Benedetta Giannini
3,
Michele Baccarani
1 and
Nicola Vianelli
1
1
Department of Hematology and Oncology L. & A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
2
Nefrology Unit, Pierantoni Hospital, 47121 Forlì, Italy
3
Istituto Oncologico Romagnolo per la Cura dei Tumori, Meldola, 47014 Forlì, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2012, 4(2), e10; https://doi.org/10.4081/hr.2012.e10
Submission received: 11 January 2012 / Revised: 5 March 2012 / Accepted: 6 March 2012 / Published: 26 June 2012

Abstract

Immunosuppressive agents are the standard therapeutic approach for immune thrombocytopenia (ITP). Their prolonged use may increase the risk of infectious complications, particularly when the patient is already at higher infectious risk. In this setting, the use of drugs with a mechanism of action alternative to immunosuppression, like thrombopoietin receptor agonists (TRAs), may find particular indication. We report the unique case of a patient with severe immunodeficiency and ITP, who experienced a serious infectious complication while on steroids treatment, and who was successfully treated with Romiplostim second- line. The present experience supports the effectiveness and safety of TRAs as early treatment of ITP patients with drug-induced immunodeficiency or with active infections.
Keywords: immune thrombocytopenia; romiplostim; TPO receptor agonist; immunodeficiency immune thrombocytopenia; romiplostim; TPO receptor agonist; immunodeficiency

Share and Cite

MDPI and ACS Style

Palandri, F.; Polverelli, N.; Lifrieri, F.; Catani, L.; Giannini, M.B.; Baccarani, M.; Vianelli, N. Romiplostim as Early Treatment of Immune Thrombocytopenia with Severe Immunodeficiency. Hematol. Rep. 2012, 4, e10. https://doi.org/10.4081/hr.2012.e10

AMA Style

Palandri F, Polverelli N, Lifrieri F, Catani L, Giannini MB, Baccarani M, Vianelli N. Romiplostim as Early Treatment of Immune Thrombocytopenia with Severe Immunodeficiency. Hematology Reports. 2012; 4(2):e10. https://doi.org/10.4081/hr.2012.e10

Chicago/Turabian Style

Palandri, Francesca, Nicola Polverelli, Francesca Lifrieri, Lucia Catani, Maria Benedetta Giannini, Michele Baccarani, and Nicola Vianelli. 2012. "Romiplostim as Early Treatment of Immune Thrombocytopenia with Severe Immunodeficiency" Hematology Reports 4, no. 2: e10. https://doi.org/10.4081/hr.2012.e10

Article Metrics

Back to TopTop